WWHS Joins Sansure Ecosystem, Launching Medical-Grade Home Health Monitoring
Recently, WWHS Biotech, Sansure Biotech, and Hunan Jinfurong Sansure Biotech Equity Investment Fund Partnership (Limited Partnership) formally signed a strategic acquisition agreement, marking WWHS Biotech's official entry into the Sansure ecosystem and the beginning of a new chapter in its development. Academician Dai Hongjie, a world-renowned scientist and member of four national academies, will lead Sansure Biotech's global strategic technology and scientific advisory panel, guiding cutting-edge technology layout and fundamental scientific research.
As a technology leader in the infrared fluorescence diagnostics field, WWHS Biotech holds globally exclusive IVD infrared fluorescence core technology. The company has developed a series of immunofluorescence detection reagents and complementary instruments for both human and veterinary applications, building a complete technology product matrix. Its technological breakthroughs span four dimensions: precision meets the needs of continuous accurate monitoring of indicators, anti-interference supports direct fingerstick blood sampling, detection limits are low enough for precise quantification of low-abundance indicators, and costs are comparable to traditional immunofluorescence.
Focusing on next-generation precision, high-sensitivity, and cost-effective in vitro diagnostic products, WWHS Biotech will engage in deep full-chain collaboration with Sansure, empowering three core scenarios: clinical diagnostics, primary care testing, and medical-grade home health monitoring, while achieving three-dimensional expansion:
